|
|
Vaccine Comparison
|
rVCG- Chlamydia-cholera |
rVCG- MOMP/HSV-2-gD |
Synthetic OMP1 Vaccine |
| Vaccine Information |
Vaccine Information |
Vaccine Information |
- Vaccine Ontology ID: VO_0004720
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Baboon
- Preparation: A multisubunit vaccine candidate co-expressing the serovar D-derived Porin B and polymorphic membrane protein-D proteins of Chlamydia trachomatis (Eko et al., 2011; Chen et al., 1998).
- Immunization Route: Intramuscular injection (i.m.)
|
- Vaccine Ontology ID: VO_0004722
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Baboon
- Preparation: A bivalent combination vaccine formulation comprising rVCG expressing chlamydial MOMP and HSV-2 glycoprotein D (Macmillan et al., 2007).
- Immunization Route: Intramuscular injection (i.m.)
|
- Vaccine Ontology ID: VO_0004240
- Type: Subunit vaccine
- Status: Research
- Antigen: Lipidic amino acid-based synthetic peptides derived from the variable domains (VD) of Chlamydia trachomatis outer membrane protein 1 (Zhong et al., 1993).
- Adjuvant:
- Immunization Route: subcutaneous injection
|
| Host Response |
Host Response |
Host Response |
|
Mouse Response
- Vaccination Protocol: Mice were immunized with rVCG constructs (Eko et al., 2011).
- Vaccine Immune Response Type: VO_0003057
- Efficacy: All vaccinated mice responded with a significant rise in vibriocidal antibody titer, the surrogate marker for protection in cholera (Eko et al., 2011).
|
Mouse Response
- Vaccination Protocol: Mice were immunized with the combination vaccine that elicited secretory IgA and IgG2a antibodies to both chlamydial and HSV-2 antigens in serum and vaginal secretions (Macmillan et al., 2007).
- Vaccine Immune Response Type: VO_0003057
- Challenge Protocol: Immunized mice then experienced a genital challenge with high doses of live Chlamydia and HSV-2 (Macmillan et al., 2007).
- Efficacy: Mice immunized with the combination vaccine were prophylactically protected (Macmillan et al., 2007).
|
Mouse Response
- Vaccination Protocol: 50 μg of peptide was injected subcutaneously with NAGO in PBS into the tail base, and was repeated at 14 day intervals (Zhong et al., 1993).
- Immune Response: NAGO elicited an antibody response similar to that in mice immunized with CFA (Zhong et al., 1993).
|
| References |
References |
References |
Chen et al., 1998: Chen I, Finn TM, Yanqing L, Guoming Q, Rappuoli R, Pizza M. A recombinant live attenuated strain of Vibrio cholerae induces immunity against tetanus toxin and Bordetella pertussis tracheal colonization factor. Infection and immunity. 1998; 66(4); 1648-1653. [PubMed: 9529093].
Eko et al., 2011: Eko FO, Okenu DN, Singh UP, He Q, Black C, Igietseme JU. Evaluation of a broadly protective Chlamydia-cholera combination vaccine candidate. Vaccine. 2011; 29(21); 3802-3810. [PubMed: 21421002].
|
Macmillan et al., 2007: Macmillan L, Ifere GO, He Q, Igietseme JU, Kellar KL, Okenu DM, Eko FO. A recombinant multivalent combination vaccine protects against Chlamydia and genital herpes. FEMS immunology and medical microbiology. 2007; 49(1); 46-55. [PubMed: 17094789].
|
Zhong et al., 1993: Zhong G, Toth I, Reid R, Brunham RC. Immunogenicity evaluation of a lipidic amino acid-based synthetic peptide vaccine for Chlamydia trachomatis. Journal of immunology (Baltimore, Md. : 1950). 1993; 151(7); 3728-3736. [PubMed: 7690812].
|
|
